Evaluation of a digital reporting and supporting tool in breast cancer prevention trials (KarmApp)
Abstract Background Anti-estrogens are widely used to reduce recurrence in breast cancer patients. The side effects often lead to treatment non-adherence and the use of anti-hormonal treatments as primary prevention in women with increased risk of breast cancer is very low. We have conducted breast...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Health Services Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12913-025-12471-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850029802597122048 |
|---|---|
| author | José Tapia Marike Gabrielson Mattias Hammarström Yvonne Wengström Jenny Bergqvist Aki Tuuliainen Mikael Eriksson Kamila Czene Per Hall Magnus Bäcklund |
| author_facet | José Tapia Marike Gabrielson Mattias Hammarström Yvonne Wengström Jenny Bergqvist Aki Tuuliainen Mikael Eriksson Kamila Czene Per Hall Magnus Bäcklund |
| author_sort | José Tapia |
| collection | DOAJ |
| description | Abstract Background Anti-estrogens are widely used to reduce recurrence in breast cancer patients. The side effects often lead to treatment non-adherence and the use of anti-hormonal treatments as primary prevention in women with increased risk of breast cancer is very low. We have conducted breast cancer prevention trials aiming to lower the adverse effects of anti-hormones, but with retained effect. For increased two-way communication and to facilitate effective reporting of adverse events we have developed a smartphone application (app), the KarmApp. The aim of our study was to explore the user frequencies of the different features of the app, and if the use is influenced by age and has changed over time. Methods Healthy women aged 40–74, attending the Swedish mammography screening program, were invited to participate in trials evaluating risk-reducing medications at different doses and formulations (KARISMA 2, N = 1,440, KARMA Creme, N = 90, and KARISMA Endoxifen, N = 240). After inclusion, participants were given instructions on how to use the app. We retrospectively evaluated the usage frequencies of the KarmApp and its various functions from 2016 to 2024. To explore the age factor attributed to KarmApp usage, age groups were formed and age was also analyzed as a continuous variable, using logistic regression. Results Of 1,770 participants, 1,646 (93.0%) used the KarmApp and there were 17,065 user interactions, corresponding to 9.6 interactions per person. “Study Activities Overview” was the feature most frequently used. A total of 2,985 adverse events were reported, 2,309 (77.4%) via the KarmApp. The remaining reports were mainly done via phone calls. The younger age, the more likely women were to use the app (p < 0.001), but 75% of women in the highest age group, 60–74 years, used the app. The proportion of users increased over time. Conclusions A vast majority chose to use the KarmApp and reported side effects via the app. More prevalent use was seen among younger participants and use increased over calendar period. Supported by our data, KarmApp exemplifies the potential of using mobile technologies in clinical trials. |
| format | Article |
| id | doaj-art-cefd74da4145438fa45816f1274d7917 |
| institution | DOAJ |
| issn | 1472-6963 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Health Services Research |
| spelling | doaj-art-cefd74da4145438fa45816f1274d79172025-08-20T02:59:24ZengBMCBMC Health Services Research1472-69632025-03-0125111410.1186/s12913-025-12471-9Evaluation of a digital reporting and supporting tool in breast cancer prevention trials (KarmApp)José Tapia0Marike Gabrielson1Mattias Hammarström2Yvonne Wengström3Jenny Bergqvist4Aki Tuuliainen5Mikael Eriksson6Kamila Czene7Per Hall8Magnus Bäcklund9Department of Medical Epidemiology and Biostatistics, Karolinska InstitutetDepartment of Medical Epidemiology and Biostatistics, Karolinska InstitutetDepartment of Medical Epidemiology and Biostatistics, Karolinska InstitutetDepartment of Neurobiology, Care Science and Society, Division of Nursing and Theme Cancer, Karolinska CCC, Karolinska University HospitalDepartment of Medical Epidemiology and Biostatistics, Karolinska InstitutetDepartment of Medical Epidemiology and Biostatistics, Karolinska InstitutetDepartment of Medical Epidemiology and Biostatistics, Karolinska InstitutetDepartment of Medical Epidemiology and Biostatistics, Karolinska InstitutetDepartment of Medical Epidemiology and Biostatistics, Karolinska InstitutetDepartment of Medical Epidemiology and Biostatistics, Karolinska InstitutetAbstract Background Anti-estrogens are widely used to reduce recurrence in breast cancer patients. The side effects often lead to treatment non-adherence and the use of anti-hormonal treatments as primary prevention in women with increased risk of breast cancer is very low. We have conducted breast cancer prevention trials aiming to lower the adverse effects of anti-hormones, but with retained effect. For increased two-way communication and to facilitate effective reporting of adverse events we have developed a smartphone application (app), the KarmApp. The aim of our study was to explore the user frequencies of the different features of the app, and if the use is influenced by age and has changed over time. Methods Healthy women aged 40–74, attending the Swedish mammography screening program, were invited to participate in trials evaluating risk-reducing medications at different doses and formulations (KARISMA 2, N = 1,440, KARMA Creme, N = 90, and KARISMA Endoxifen, N = 240). After inclusion, participants were given instructions on how to use the app. We retrospectively evaluated the usage frequencies of the KarmApp and its various functions from 2016 to 2024. To explore the age factor attributed to KarmApp usage, age groups were formed and age was also analyzed as a continuous variable, using logistic regression. Results Of 1,770 participants, 1,646 (93.0%) used the KarmApp and there were 17,065 user interactions, corresponding to 9.6 interactions per person. “Study Activities Overview” was the feature most frequently used. A total of 2,985 adverse events were reported, 2,309 (77.4%) via the KarmApp. The remaining reports were mainly done via phone calls. The younger age, the more likely women were to use the app (p < 0.001), but 75% of women in the highest age group, 60–74 years, used the app. The proportion of users increased over time. Conclusions A vast majority chose to use the KarmApp and reported side effects via the app. More prevalent use was seen among younger participants and use increased over calendar period. Supported by our data, KarmApp exemplifies the potential of using mobile technologies in clinical trials.https://doi.org/10.1186/s12913-025-12471-9Adverse event reportingSmartphone applicationRandomized clinical trialeHealthmHealthBreast cancer prevention |
| spellingShingle | José Tapia Marike Gabrielson Mattias Hammarström Yvonne Wengström Jenny Bergqvist Aki Tuuliainen Mikael Eriksson Kamila Czene Per Hall Magnus Bäcklund Evaluation of a digital reporting and supporting tool in breast cancer prevention trials (KarmApp) BMC Health Services Research Adverse event reporting Smartphone application Randomized clinical trial eHealth mHealth Breast cancer prevention |
| title | Evaluation of a digital reporting and supporting tool in breast cancer prevention trials (KarmApp) |
| title_full | Evaluation of a digital reporting and supporting tool in breast cancer prevention trials (KarmApp) |
| title_fullStr | Evaluation of a digital reporting and supporting tool in breast cancer prevention trials (KarmApp) |
| title_full_unstemmed | Evaluation of a digital reporting and supporting tool in breast cancer prevention trials (KarmApp) |
| title_short | Evaluation of a digital reporting and supporting tool in breast cancer prevention trials (KarmApp) |
| title_sort | evaluation of a digital reporting and supporting tool in breast cancer prevention trials karmapp |
| topic | Adverse event reporting Smartphone application Randomized clinical trial eHealth mHealth Breast cancer prevention |
| url | https://doi.org/10.1186/s12913-025-12471-9 |
| work_keys_str_mv | AT josetapia evaluationofadigitalreportingandsupportingtoolinbreastcancerpreventiontrialskarmapp AT marikegabrielson evaluationofadigitalreportingandsupportingtoolinbreastcancerpreventiontrialskarmapp AT mattiashammarstrom evaluationofadigitalreportingandsupportingtoolinbreastcancerpreventiontrialskarmapp AT yvonnewengstrom evaluationofadigitalreportingandsupportingtoolinbreastcancerpreventiontrialskarmapp AT jennybergqvist evaluationofadigitalreportingandsupportingtoolinbreastcancerpreventiontrialskarmapp AT akituuliainen evaluationofadigitalreportingandsupportingtoolinbreastcancerpreventiontrialskarmapp AT mikaeleriksson evaluationofadigitalreportingandsupportingtoolinbreastcancerpreventiontrialskarmapp AT kamilaczene evaluationofadigitalreportingandsupportingtoolinbreastcancerpreventiontrialskarmapp AT perhall evaluationofadigitalreportingandsupportingtoolinbreastcancerpreventiontrialskarmapp AT magnusbacklund evaluationofadigitalreportingandsupportingtoolinbreastcancerpreventiontrialskarmapp |